Submitted to Health Canada in April 2022.
This publication has been archived on the CCSA website and was current when it was published. It is available for reference or research purposes.
Summarizes information on the availability of counterfeit oxycodone tablets containing fentanyl, and advises that the presence of fentanyl in counterfeit oxycodone (brand name OxyContin®) pills increases the risk of overdose.
Supporting Reintegration in Corrections by Addressing Problematic Substance Use (Report at a Glance)
Summarizes the findings of an environmental scan with the same title. One key message is that addressing problematic substance use in prisons can lead to a reduction in criminality, successful reintegration and a cost savings for corrections.
Examines the regulatory frameworks implemented for the legalization of cannabis in Colorado and Washington State.
This conference brings together delegates drawn from the areas of public health and safety, traffic, and transport psychology, public health, law, medicine, economics, law enforcement, public policy, education, pharmacology, toxicology, forensic…
Summarizes the landscape of operational and implementation guidelines for integrated mental health, substance use and concurrent (mental health and substance use) disorder service provision in Canada and internationally.
Reviews research about the effects of smoking cannabis on the cardiovascular and respiratory systems (heart and lungs).
Explores the available clinical evidence and research on using cannabis and cannabinoids for health conditions including Alzheimer disease, anxiety, cancer, depression, epilepsy, fibromyalgia, multiple sclerosis, pain, Parkinson disease,…
Presents ways that Canada can move towards a recovery-oriented system of care, based on six guiding principles for recovery, the findings from the Life in Recovery survey and the experience of professionals.
